621: SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF TPM502, A MIXTURE OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF CELIAC DISEASE (CED)

Authors
Category Primary study
ConferenceDDW® 2025
Year 2025
This article has no abstract
Epistemonikos ID: 91df07fdb71bce8371564dd310ba3ac6b83290e1
First added on: Nov 07, 2025